Global Large Molecule Bioanalytical Testing Services Market Report 2022 to 2029: Featuring Charles River, Medpace, WuXi AppTec and Eurofins Scientific Among Others

Company Logo
Company Logo

Dublin, Dec. 01, 2022 (GLOBE NEWSWIRE) -- The "Large Molecule Bioanalytical Testing Services Market Analysis by Phase, by Type, by Test Type, by Therapeutic Area, by End user by Region - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

The large molecule bioanalytical testing services market size is estimated to be USD 1.7 billion in 2021 and is expected to witness a CAGR of 11.58%% during the forecast period 2022-2029.

The market is expected to grow due to increased complication of product designs and engineering, and rising demands for advanced and high-quality large molecule bioanalytical testing services. Other factors driving market expansion include increased regulatory supervision and a significant risk of product failure. However, concerns about legality while outsourcing is expected to limit the market growth.

By Phase

Based on phase, the market is bifurcated into clinical and pre-clinical. In 2021, the clinical segment accounted for the highest revenue share owing to increased demand for cutting-edge technology, increased production of biologics, and rising demand for individualized orphan medicines & medications. However, the rising incidence of chronic illnesses and the demand for clinical trials in emerging nations is also helping the market growth.

By Type

On the basis of type, the market is categorized into ADA, pharmacokinetics, and others. In 2021, the pharmacokinetics segment accounted for the highest revenue share due to the invention and use of cutting-edge technologies in pharmacokinetics research.

By Test Type

Based on test type, the market is segregated into Bioequivalence, bioavailability, ADME, PD, PK, and other tests. In 2021, the bioavailability segment accounted for the highest revenue share owing to the significant need for these services in the production of generic drugs.

By Therapeutic Area

On the basis of therapeutic area, the market is categorized into infectious disease, oncology, neurology, cardiology, and others. In 2021, the oncology segment accounted for the highest revenue share due to increasing cancer incidence, the fast-growing senior population, and unhealthy lifestyles are the key reasons projected to fuel category growth.

By End user

Based on end user, the market is bifurcated into large firms and SMEs. In 2021, the SMEs segment accounted for the highest revenue share owing to SMEs bringing more approaches to innovation.

Regional Markets

Asia Pacific held the largest revenue share in the large molecule bioanalytical testing services market in 2021, and it is predicted to continue to do so throughout the forecast period. This is due to significant technology improvements and rising demand for bioanalytical testing services. Furthermore, biopharmaceutical companies are concentrating their attention in the United States due to the country's booming healthcare industry. Bioanalytical testing services businesses are increasing their expenditures, the biopharmaceutical industry is increasing its R&D expenditure, and favourable regulatory changes are all driving to regional market growth.

Competitor Insights

Some of the key players operating in the large molecule bioanalytical testing services market are Charles River (US), Medpace (US), WuXi AppTec (China), Eurofins Scientific (Luxembourg), IQVIA, Inc. (US), SGS SA (Switzerland), Laboratory Corporation of America Holdings (US), Intertek Group plc (UK), PRA Health Sciences (US), Syneos Health (US), ICON plc (Ireland), Frontage Labs (US), PPD, Inc. (US), PAREXEL International Corporation (US), Almac Group (UK), Celerion (US), Altasciences (US), BioAgilytix Labs (US), Lotus Labs Pvt. Ltd. (India), and LGS Limited (UK).

Key Topics Covered:

1. Research Methodology

2. Introduction: Large Molecule Bioanalytical Testing Services

3. Executive Summary
3.1.Global Market Scenario
3.2.Segment Market Scenario
3.3.Geographic Market Scenario
3.4.COVID-19 Impact
3.5.Competitive Landscape

4. Market Dynamics
4.1. Market Drivers
4.2.Market Restraint
4.3.Market Opportunities
4.4.Market Trends
4.5.Market Challenges

5. Market Environment Analysis
5.1.Porter's 5 Forces Analysis
5.2.PESTEL Analysis
5.3.Value Chain Analysis
5.4.SWOT Analysis
5.5.Benchmark

6. COVID-19 Impact Analysis: Large Molecule Bioanalytical Testing Services Market
6.1.COVID-19: Overview
6.2.COVID-19 Impact on the Global Market
6.3.COVID-19 Impact on the Regional Markets

7. Market Analysis by Phase
7.1.Clinical
7.1.1.Clinical Market Forecast, 2021-2029 (USD Million)
7.2.Pre-clinical
7.2.1.Pre-clinical Market Forecast, 2021-2029 (USD Million)

8. Market Analysis by Type
8.1.ADA
8.1.1.ADA Market Forecast, 2021-2029 (USD Million)
8.2.Pharmacokinetics
8.2.1.Pharmacokinetics Market Forecast, 2021-2029 (USD Million)
8.3.Others
8.3.1.Others Market Forecast, 2021-2029 (USD Million)

9. Market Analysis by Test Type
9.1.Bioequivalence
9.1.1.Bioequivalence Market Forecast, 2021-2029 (USD Million)
9.2.Bio availability
9.2.1.Bio availability Market Forecast, 2021-2029 (USD Million)
9.3.ADME
9.3.1.ADME Market Forecast, 2021-2029 (USD Million)
9.4.PD
9.4.1.PD Market Forecast, 2021-2029 (USD Million)
9.5.PK
9.5.1.PK Market Forecast, 2021-2029 (USD Million)
9.6.Others
9.6.1.Others Market Forecast, 2021-2029 (USD Million)

10. Market Analysis by Therapeutic Area
10.1.Infectious Disease
10.1.1.Infectious Disease Market Forecast, 2021-2029 (USD Million)
10.2.Oncology
10.2.1.Oncology Market Forecast, 2021-2029 (USD Million)
10.3.Neurology
10.3.1.Neurology Market Forecast, 2021-2029 (USD Million)
10.4.Cardiology
10.4.1.Cardiology Market Forecast, 2021-2029 (USD Million)
10.5.Others
10.5.1.Others Market Forecast, 2021-2029 (USD Million)

11. Market Analysis by End user
11.1.Large Firms
11.1.1.Large Firms Market Forecast, 2021-2029 (USD Million)
11.2.SMEs
11.2.1.SMEs Market Forecast, 2021-2029 (USD Million)

12. Regional Market Analysis
12.1.Regional Market Trends
12.2.Regional Market: Comparative Analysis

13. North America Large Molecule Bioanalytical Testing Services Market

14. Europe Large Molecule Bioanalytical Testing Services Market

15. Asia Pacific Large Molecule Bioanalytical Testing Services Market

16. Latin America Large Molecule Bioanalytical Testing Services Market

17. MEA Large Molecule Bioanalytical Testing Services Market

18. Competitor Analysis
18.1.Market Share Analysis, 2021 & 2029
18.2.Competitive Mapping
18.3.Key Players Market Place Analysis
18.4.Major Recent Developments

19. Company Profiles
19.1.Charles River (US)
19.1.1.Company Snapshot
19.1.2.Company Overview
19.1.3.Financials
19.1.4.Phase Benchmarking
19.1.5.Recent Developments
19.2.Medpace (US)
19.2.1.Company Snapshot
19.2.2.Company Overview
19.2.3.Financials
19.2.4.Phase Benchmarking
19.2.5.Recent Developments
19.3.WuXi AppTec (China)
19.3.1.Company Snapshot
19.3.2.Company Overview
19.3.3.Financials
19.3.4.Phase Benchmarking
19.3.5.Recent Developments
19.4.Eurofins Scientific (Luxembourg)
19.4.1.Company Snapshot
19.4.2.Company Overview
19.4.3.Financials
19.4.4.Phase Benchmarking
19.4.5.Recent Developments
19.5.IQVIA, Inc. (US)
19.5.1.Company Snapshot
19.5.2.Company Overview
19.5.3.Financials
19.5.4.Phase Benchmarking
19.5.5.Recent Developments
19.6.SGS SA (Switzerland)
19.6.1.Company Snapshot
19.6.2.Company Overview
19.6.3.Financials
19.6.4.Phase Benchmarking
19.6.5.Recent Developments
19.7.Laboratory Corporation of America Holdings (US)
19.7.1.Company Snapshot
19.7.2.Company Overview
19.7.3.Financials
19.7.4.Phase Benchmarking
19.7.5.Recent Developments
19.8.Intertek Group plc (UK)
19.8.1.Company Snapshot
19.8.2.Company Overview
19.8.3.Financials
19.8.4.Phase Benchmarking
19.8.5.Recent Developments
19.9.PRA Health Sciences (US)
19.9.1.Company Snapshot
19.9.2.Company Overview
19.9.3.Financials
19.9.4.Phase Benchmarking
19.9.5.Recent Developments
19.10.Syneos Health (US)
19.10.1.Company Snapshot
19.10.2.Company Overview
19.10.3.Financials
19.10.4.Phase Benchmarking
19.10.5.Recent Developments
19.11. ICON plc (Ireland)
19.11.1.Company Snapshot
19.11.2.Company Overview
19.11.3.Financials
19.11.4.Phase Benchmarking
19.11.5.Recent Developments
19.12. Frontage Labs (US)
19.12.1.Company Snapshot
19.12.2.Company Overview
19.12.3.Financials
19.12.4.Phase Benchmarking
19.12.5.Recent Developments
19.13. PPD, Inc. (US)
19.13.1.Company Snapshot
19.13.2.Company Overview
19.13.3.Financials
19.13.4.Phase Benchmarking
19.13.5.Recent Developments
19.14. PAREXEL International Corporation (US)
19.14.1.Company Snapshot
19.14.2.Company Overview
19.14.3.Financials
19.14.4.Phase Benchmarking
19.14.5.Recent Developments
19.15. Almac Group (UK)
19.15.1.Company Snapshot
19.15.2.Company Overview
19.15.3.Financials
19.15.4.Phase Benchmarking
19.15.5.Recent Developments
19.16.Others Prominent Players

20. Conclusion & Recommendations

For more information about this report visit https://www.researchandmarkets.com/r/ry9a7f

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900